Switch to dolutegravir is well tolerated in Thais with HIV infection

INTRODUCTION: Dolutegravir (DTG) is recommended as part of first‐line antiretroviral therapy (ART) for people living with HIV(PLHIV). We sought to determine the rate of adverse events (AEs) and discontinuations among Thais treated during acute HIV infection (AHI) and switched to DTG‐based regimens....

Descripción completa

Detalles Bibliográficos
Autores principales: Goh, Orlanda Q, Colby, Donn J, Pinyakorn, Suteeraporn, Sacdalan, Carlo, Kroon, Eugène, Chan, Phillip, Chomchey, Nitiya, Kanaprach, Ratchapong, Prueksakaew, Peeriya, Suttichom, Duanghathai, Trichavaroj, Rapee, Spudich, Serena, Robb, Merlin L, Phanuphak, Praphan, Phanuphak, Nittaya, Ananworanich, Jintanat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621926/
https://www.ncbi.nlm.nih.gov/pubmed/31294931
http://dx.doi.org/10.1002/jia2.25324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621926/
https://www.ncbi.nlm.nih.gov/pubmed/31294931
http://dx.doi.org/10.1002/jia2.25324

Ejemplares similares